Medtronic: CRT-Ds are a bargain

Medtronic ($MDT) is trying to convince you that cardiac resynchronization therapy devices (CRT-Ds) are a bargain. The Minnesota medical device giant released the results of an economic analysis of the RAFT trial that showed the implant is a cost-effective way to treat patients with mildly symptomatic heart failure. They found that the cost "per quality adjusted life year" using the company's device amounted to $33,025 for patients with New York Heart Association-designated Class II or III heart failure. That is compared to at least $50,000 for other serious chronic conditions, the company said. Medtronic released the analysis a month after the FDA granted an expanded indication for the company's CRT-D devices, allowing them to be used earlier in patients with--you guessed it--mildly symptomatic heart failure. Release

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.